

**IN THE CLAIMS**

Claims 1 - 52 (Canceled)

53. (Currently amended) A soluble compound that is directed to an outer membrane of a cell, wherein the soluble compound comprises:

- (1) a soluble polypeptide that inhibits complement; and
- (2) a membrane localization reagent, wherein the membrane localization reagent is soluble and comprises:
  - (a) at least one lipophilic binding element comprising aliphatic acyl groups;
  - (b) a hydrophilic peptide binding element comprising ~~at least one basic amino acid~~ basic amino acids, wherein the hydrophilic binding element is bound to the lipophilic element; and
  - (c) a linker that covalently binds ~~the~~ a therapeutic agent to the hydrophilic peptide binding element of the membrane localization reagent to form the soluble compound.

54. (Previously added) The soluble compound of claim 53, wherein the hydrophilic peptide binding element comprises lysine residues.

55. (Previously added) The soluble compound of claim 53, wherein the hydrophilic peptide binding element comprises arginine residues.

56. (Previously added) The soluble compound of claim 53, wherein the soluble peptide that inhibits complement is a soluble CD59 polypeptide or a soluble DAF polypeptide.

57. (Currently amended) The soluble compound of claim 53, wherein the lipophilic binding element and the [[a]] hydrophilic peptide binding element each have a dissociation constant of  $1\mu\text{M}$  to  $1\text{mM}$  for a membrane.

58. (Currently amended) The soluble compound of claim 53, wherein the lipophilic binding element and the [[a]] hydrophilic peptide binding element each have a molecular weight of less than 5 kilodaltons.

59. (Currently amended) The soluble compound of claim 53, wherein the soluble ~~compounds~~ compound has a dissociation constant ~~affinity~~ of 0.01 to 10 nM for a membrane.

60. (Currently amended) A pharmaceutical composition that is directed to an outer membrane of a cell, comprising  
(1) a soluble polypeptide that inhibits complement;

(2) a membrane localization reagent, wherein the membrane localization reagent is soluble and comprises:

- (a) at least one lipophilic binding element comprising aliphatic acyl groups;
- (b) a hydrophilic peptide binding element comprising ~~at least one basic amino acid~~ basic amino acids, wherein the hydrophilic binding element is bound to the lipophilic element; and
- (c) a linker that covalently binds ~~the a~~ therapeutic agent to the hydrophilic peptide binding element of the membrane localization reagent to form the soluble compound; and

(3) a pharmaceutically acceptable carrier or excipient.

61. (Previously added) The pharmaceutical composition of claim 60, wherein the hydrophilic peptide binding element comprises lysine residues.

62. (Previously added) The pharmaceutical composition of claim 60, wherein the hydrophilic peptide binding element comprises arginine residues.

63. (Previously added) The pharmaceutical composition of claim 60, wherein the soluble peptide that inhibits complement is a soluble CD59 polypeptide or a soluble DAF polypeptide.

64. (Currently amended) The pharmaceutical composition of claim 60, wherein the lipophilic binding element and the  $\alpha$  hydrophilic peptide binding element each have a dissociation constant of  $1\mu\text{M}$  to  $1\text{mM}$  for a membrane.

65. (Currently amended) The pharmaceutical composition of claim 60, wherein the lipophilic binding element and the [[a]] hydrophilic peptide binding element each have a molecular weight of less than 5 kilodaltons.

66. (Currently amended) The pharmaceutical composition of claim 60, wherein the soluble ~~compounds~~ compound has a dissociation constant affinity of 0.01 to 10 nM for a membrane.